-
The lift study (Long-Term Intervention on Fractures with Tibolone) was a randomized, placebo-controlled multicenter trial in 22 countries of tibolone, 1.25 mg, given daily over 3 years.
-
The objective of this study was to examine and compare the clinical behavior and outcome of uterine carcinosarcoma relative to grade 3 endometrioid carcinoma.
-
Fetal fibronectin is now being used in many hospitals to separate out those with preterm contractions (PTCs) who are in true labor from those with contractions who are not (and, therefore, not requiring tocolytics or hospitalization).
-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.
-
-
Estrogen treatment (but not estrogen given along with progestin) seems associated with gastro-esophageal reflux (GER) in postmenopausal women. Weight gain increases risk.
-
Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.
-
The ECG shown above was obtained from a patient who was seen in the office with atypical chest pain. Is there cause for concern?
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
